多重癌症筛检市场 - 2018-2028 年全球产业规模、份额、趋势、竞争、机会和预测，按测试类型、技术、样本、方法、癌症类型、按应用、最终用户、地区和竞赛

多种癌症筛检市场正在全球范围内获得巨大的关注。多种癌症筛检有可能从单一血液样本中发现多种癌症。目前世界上可进行的多种癌症筛检测试包括血液检查、影像学测试、基因测试、液体活检、粪便测试等。在各种类型的测试中，液体活检测试最为突出，因为它可以快速进行，提供基因组、蛋白质组和代谢组信息，并且比组织活检的侵入性更小。乳癌、肺癌、大肠癌、胰臟癌、肝癌、卵巢癌、胃癌、食道癌和摄护腺癌是一些可以透过多种癌症筛检测试轻鬆检测到的癌症类型。世界各国尤其是澳洲、纽西兰、爱尔兰、匈牙利和美国的癌症盛行率不断上升，增加了预测期内对多种癌症筛检测试的需求。政府为提高各国医疗服务品质而提供的支援的成长也正在推动预测期内的全球多癌症筛检市场。此外，政府每年都积极参与采取预防措施，透过实施新的卫生政策和引入医疗保险来控制癌症在各国的盛行率。此外，该国老年人口的成长以及与人类相关的某些类型癌症的盛行率增加，尤其是在老年时期，预计也将在未来几年推动全球多癌症筛检市场的发展。

慢性病盛行率增加

癌症是全球主要死亡原因之一，由于人口老化、生活方式的改变和环境因素等多种因素，预计未来几年癌症的发生率将持续上升。发展中国家地区最常见的癌症类型是乳癌。例如，在美国，2023 年约有 3,00,590 例乳癌新病例被诊断为乳癌。继乳癌之后世界上正在出现的另一种癌症包括肺癌、大肠癌、摄护腺癌、胃肠癌、肝癌和子宫颈癌。根据世界卫生组织（WHO）2022年发布的报告，2020年全球约有226万例乳癌病例，其次是肺癌221万例、结肠癌和直肠癌193万例、癌症141万例。前列腺癌、120万例皮肤癌（非黑色素瘤）和109 万例胃癌。全球癌症盛行率不断上升，导致各国死亡率逐年显着上升。根据世界癌症研究基金会发布的全球癌症发生率报告，丹麦的癌症发生率最高，为每10万人口326.1例，其次是爱尔兰，每10万人中有317例，澳洲有314.1例，纽西兰是每10万人中癌症发生率最高的国家。每 10 万人口中有 309.2 例，比利时有 306.8 例，依此类推。多种癌症的盛行率不断上升，增加了世界对多癌筛检设备的需求，这种设备可以提前检测多种癌症的症状，从而降低世界死亡率，预计这将进一步推动全球多癌症筛检市场的发展。预测期。

市场概况
预测期	2024-2028
2022 年市场规模	90106万美元
2028 年市场规模	190143万美元
2023-2028 年复合年增长率	13.22%
成长最快的细分市场	医院
最大的市场	北美洲

政府支持的增加

多癌筛检市场是指开发和销售可以检测个人各种癌症类型的测试和服务。政府的支持可以在推动该市场的成长方面发挥重要作用。许多政府正在投资癌症筛检测试和技术的研发。例如，美国国家癌症研究所为各种多癌症筛检试验和研究提供资金。它们在製定激励或强制癌症筛检的政策方面也发挥着至关重要的作用。

老年人口增加

随着年龄的增长，人们患癌症的风险增加，这刺激了该国老年人口对癌症筛检测试的需求。通常在全国老年人中诊断出的一些最常见的癌症类型包括胰腺癌、皮肤癌、膀胱癌、淋巴瘤、白血病、前列腺癌等。根据国际癌症控制联盟（UICC）2023年发布的报告，70岁以上老年人中约有720万人被诊断出罹患癌症，其中约440万人因癌症死亡。然而，近年来老年人预防癌症的意识不断增强，预计在预测期内全球多癌筛检市场将实现利润丰厚的成长。

市场区隔

全球多癌筛检市场根据测试类型、技术、样本、方法、癌症类型、应用、最终用户和地区进行细分。就测试类型而言，多重癌症筛检市场分为实验室开发测试（LDT）和体外诊断（IVD）。从技术角度来看，全球多癌筛检市场分为新一代定序（NGS）、聚合酶炼式反应（PCR）、免疫组织化学（IHC）、萤光原位杂交（FISH）等技术。根据样本，多癌筛检市场分为组织、血液、唾液和口腔拭子等。基于这种方法，市场被细分为 DNA、RNA 和蛋白质。根据癌症类型，全球多癌筛检市场分为乳癌和妇科、胃肠道、内分泌、泌尿生殖、皮肤、脑部/神经系统、肉瘤、血液恶性肿瘤、肺癌、头颈癌和其他癌症类型。根据应用，市场分为临床和研究。根据最终用户，市场分为医院、诊断和临床实验室、学术研究机构和其他最终用户。

市场参与者

Agilent Technologies, Inc., Atara Biotherapeutics, Inc., Burning Rock Biotech Limited, Exact Sciences Corp., F. Hoffmann-La Roche Ltd., Fulgent Genetics, Inc., 臻及生技有限公司, Guardant Health, Inc. 、 Illumina, Inc. (GRAIL, LLC.) 和Konica Minolta, Inc. (Ambry Genetics)。

报告范围：

在本报告中，除了以下详细介绍的产业趋势外，全球多癌症筛检市场也分为以下几类。

多种癌症筛检市场，依测试类型：

• 实验室开发的测试 (LDT)
• 体外诊断 (IVD)

多重癌症筛检市场（按技术）：

• 新一代定序 (NGS)
• 聚合酶炼式反应 (PCR)
• 免疫组织化学 (IHC)
• 萤光原位杂交 (FISH)
• 其他技术

多种癌症筛检市场（按样本）：

• 组织
• 血
• 唾液和颊拭子
• 其他的

多种癌症筛检市场，依方法：

• 脱氧核糖核酸
• 核糖核酸
• 蛋白质

多种癌症筛检市场，依癌症类型划分：

• 乳房及妇科
• 胃肠道
• 内分泌
• 泌尿生殖系统
• 皮肤
• 大脑/神经系统
• 肉瘤
• 血液系统恶性肿瘤
• 肺
• 头部和颈部
• 其他癌症类型

多癌筛检市场，按应用：

• 临床
• 研究

多种癌症筛检市场，依最终用户划分：

• 医院
• 诊断和临床实验室
• 学术研究机构
• 其他最终用户

全球多癌筛检市场（按地区）：

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 亚太
• 中国
• 印度
• 韩国
• 澳洲
• 日本
• 欧洲
• 德国
• 法国
• 英国
• 西班牙
• 义大利
• 南美洲
• 巴西
• 阿根廷
• 哥伦比亚
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿联酋

竞争格局

• 公司简介：全球多癌筛检市场主要公司的详细分析。

可用的客製化：

• 根据给定的市场资料，TechSci Research 可根据公司的具体需求提供客製化服务。该报告可以使用以下自订选项：

公司资讯

• 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

• 市场定义
• 市场范围
  • 涵盖的市场
  • 考虑学习的年份
  • 主要市场区隔

第 2 章：研究方法

• 研究目的
• 基线方法
• 主要产业伙伴
• 主要协会和二手资料来源
• 预测方法
• 数据三角测量与验证
• 假设和限制

第 3 章：执行摘要

• 市场概况
• 主要市场细分概述
• 主要市场参与者概述
• 重点地区/国家概况
• 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球多癌症筛检市场展望

• 市场规模及预测
  • 按价值和数量
• 市占率及预测
  • 依测试类型（实验室开发测试 (LDT)、体外诊断 (IVD)）
  • 依技术（次世代定序 (NGS)、聚合酶链反应 (PCR)、免疫组织化学 (IHC)、萤光原位杂交 (FISH) 和其他技术）
  • 依样本（组织、血液、唾液和口腔拭子等）
  • 依方法（DNA、RNA 和蛋白质）
  • 依癌症类型（乳癌和妇科、胃肠道、内分泌、泌尿生殖、皮肤、脑/神经系统、肉瘤、血液恶性肿瘤、肺癌、头颈癌和其他癌症类型）
  • 按应用（临床、研究）
  • 按最终用户（医院、诊断和临床实验室、学术研究机构和其他最终用户）
  • 按地区
  • 按公司划分 (2022)
• 产品市场地图

第 6 章：北美多癌症筛检市场展望

• 市场规模及预测
  • 按价值和数量
• 市占率及预测
  • 按测试类型
  • 依技术
  • 按样品
  • 依方法
  • 按癌症类型
  • 按应用
  • 按最终用户
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第 7 章：欧洲多癌症筛检市场展望

• 市场规模及预测
  • 按价值和数量
• 市占率及预测
  • 按测试类型
  • 依技术
  • 按样品
  • 依方法
  • 按癌症类型
  • 按应用
  • 按最终用户
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太地区多种癌症筛检市场展望

• 市场规模及预测
  • 按价值和数量
• 市占率及预测
  • 按测试类型
  • 依技术
  • 按样品
  • 依方法
  • 按癌症类型
  • 按应用
  • 按最终用户
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第 9 章：南美洲多癌筛检市场展望

• 市场规模及预测
  • 按价值和数量
• 市占率及预测
  • 按测试类型
  • 依技术
  • 按样品
  • 依方法
  • 按癌症类型
  • 按应用
  • 按最终用户
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲多癌症筛检市场展望

• 市场规模及预测
  • 按价值和数量
• 市占率及预测
  • 按测试类型
  • 依技术
  • 按样品
  • 依方法
  • 按癌症类型
  • 按应用
  • 按最终用户
  • 按国家/地区
• MEA：国家分析
  • 南非多种癌症筛检
  • 沙乌地阿拉伯多种癌症筛检
  • 阿联酋多种癌症筛检

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

第 13 章：大环境分析

第 14 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第15章：竞争格局

• 商业概览
• 公司概况
• 产品与服务
• 财务（上市公司）
• 最近的发展
• SWOT分析
  • Agilent Technologies, Inc.
  • Atara Biotherapeutics, Inc.
  • Burning Rock Biotech Limited
  • Exact Sciences Corp.
  • F. Hoffmann-La Roche Ltd.
  • Fulgent Genetics, Inc.
  • Genecast Biotechnology Co., Ltd.
  • Guardant Health, Inc.
  • Illumina, Inc. (GRAIL, LLC.)
  • Konica Minolta, Inc. (Ambry Genetics.)

第 16 章：策略建议

第 17 章：关于我们与免责声明

Multi-cancer screening market is gaining significant traction across the world. Multi-cancer screening has the potential to find more than one type of cancer from a single sample of blood. Several types of multicancer screening tests that are currently accessible in the world include blood tests, imaging tests, genetic tests, liquid biopsy, stool tests, and others. Among various types of tests, the liquid biopsy test is the most prominent since it can be carried out rapidly, provides genomic, proteomic, and metabolomic information, and is less invasive than tissue biopsies. Breast cancer, lung cancer, colorectal cancer, pancreatic cancer, liver cancer, ovarian cancer, stomach cancer, esophageal cancer, and prostate cancer are some of the cancer types that can be easily detected through multi-cancer screening tests. The increasing prevalence of cancer in various countries of the world especially Australia, New Zealand, Ireland, Hungary, and the United States of America is increasing the demand for multicancer screening tests during the forecast period. Growth in the support provided by the government to improve the quality of medical services provided in every country is also propelling the global multicancer screening market in the forecast period. Moreover, the government is actively participating in taking preventive measures, for controlling the prevalence of cancer in every country by the implementation of new health policies and introduction of healthcare insurance every year. Furthermore, the growth in the geriatric population of the country and the increase in the prevalence of certain types of cancers, which are associated with people, especially during their elder age is also expected to boost the global multicancer screening market in upcoming years.

Increasing Prevalence of Chronic Diseases

Cancer is one of the leading causes of death worldwide, and the incidence of cancer is expected to continue to rise in the coming years due to various factors such as aging populations, changes in lifestyle, and environmental factors. The most common type of cancer prevailing in the regions of developing countries is breast cancer. For instance, in the United States of America, around 3,00,590 new cases of breast cancer were diagnosed of breast cancer in 2023. Another type of cancers, which is emerging in the world followed by breast cancer comprises of lung cancer, colorectal cancer, prostate cancer, stomach cancer, liver cancer, and cervical cancer. According to the report published by the World Health Organization (WHO) in 2022, around 2.26 million cases of breast cancer were worldwide in 2020, followed by 2.21 million cases of lung cancer, 1.93 million cases of colon and rectum cancer, 1.41 million cases of prostate cancer, 1.20 million cases of skin cancer (non-melanoma) and 1.09 million cases of stomach cancer. The growing prevalence of cancer in the world is resulting in a noticeable rise in the mortality rate of each country with every passing year. As per the report published by World Cancer Research Fund on global cancer rates, it has been concluded that Denmark has recorded the highest cancer rate of 326.1 cases per 1,00,000 population, followed by Ireland with 317 cases, Australia with 314.1 cases, New Zealand with 309.2 cases and Belgium with 306.8 per 1,00,000 population and so on. The growing prevalence of several kinds of cancers is increasing the demand for multicancer screening devices in the world which can detect symptoms of multiple cancer beforehand and can thereby decrease the mortality rate of the world, which is further expected to propel the global multicancer screening market during the forecast period.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD901.06 Million
Market Size 2028	USD1901.43 Million
CAGR 2023-2028	13.22%
Fastest Growing Segment	Hospitals
Largest Market	North America

Growth in Government Support

The Multicancer screening market refers to the development and sale of tests and services that can detect various types of cancers in individuals. Government support can play a significant role in driving growth in this market. Many governments are investing in research and development of cancer screening tests and technologies. For instance, the National Cancer Institute in the United States provides funding for various multicancer screening trials and studies. They also play a crucial role in shaping policies that incentivize or mandate cancer screening.

Moreover, governing bodies of every country also launch public awareness campaigns to promote cancer screening and early detection. These campaigns focus on educating people about the importance of regular screening for cancer and encourage them to get screened.

Furthermore, governments can collaborate with private companies and organizations to advance cancer screening technologies. In the case of cancer screening programs, Public-private partnerships (PPPs) may be formed to increase awareness and access to screening, reduce costs, and improve the quality of screening services. Development in the support provided by the government to reduce the prevalence of cancer in every country along with the introduction of new health insurance plans every year is expected to register impressive growth in the global multicancer screening market in upcoming years.

Increase in Geriatric Population

With growing age, the risk of developing cancer increases in people, which is fueling the demand for cancer screening tests among the elderly population in the country. Some of the most common types of cancers, which are usually diagnosed in elderly people across the country include pancreatic cancer, skin cancer, bladder cancer, lymphoma, leukemia, prostate cancer, and others. According to the report published by Union for International Cancer Control (UICC) in 2023, it has been observed that around 7.2 million of those above 70 years of age were diagnosed with cancer and approximately 4.4 million of them resulted in death due to cancer. However, growing awareness among geriatric people in passing years to prevent themselves from cancer is expected to register a lucrative growth in the global multicancer screening market during the forecast period.

Market Segmentation

The global multicancer screening market is segmented based on test type, technology, sample, method, cancer type, application, end user, and region. In terms of test type, the multicancer screening market is categorized into laboratory-developed tests (LDTs) and in-vitro diagnostics (IVDs). Based on technology, the global multicancer screening market is fragmented into next-generation sequencing (NGS), polymerase chain reaction (PCR), Immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH), and other technologies. Based on sample, the multicancer screening market is categorized into tissue, blood, saliva and buccal swab, and others. Based on this method, the market is segmented into DNA, RNA, and proteins. Based on cancer type, the global multicancer screening market is fragmented into breast and gynecologic, gastrointestinal, endocrine, genitourinary, skin, brain/nervous system, sarcoma, hematological malignancies, lung, head and neck, and other cancer types. Based on application, the market is segmented into clinical and research. Based on end user, the market is segmented into hospitals, diagnostic and clinical laboratories, academic research institutions, and other end users.

Market Players

Agilent Technologies, Inc., Atara Biotherapeutics, Inc., Burning Rock Biotech Limited, Exact Sciences Corp., F. Hoffmann-La Roche Ltd., Fulgent Genetics, Inc., Genecast Biotechnology Co., Ltd., Guardant Health, Inc., Illumina, Inc. (GRAIL, LLC.), and Konica Minolta, Inc. (Ambry Genetics).

Report Scope:

In this report, the global multicancer screening market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Multicancer Screening Market, By Test Type:

• Laboratory Developed Tests (LDTs)
• In-Vitro Diagnostics (IVDs)

Multicancer Screening Market, By Technology:

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)
• Fluorescence In-Situ Hybridization (FISH)
• Other Technologies

Multicancer Screening Market, By Sample:

• Tissue
• Blood
• Saliva and Buccal Swab
• Others

Multicancer Screening Market, By Method:

• DNA
• RNA
• Proteins

Multicancer Screening Market, By Cancer Type:

• Breast and Gynecologic
• Gastrointestinal
• Endocrine
• Genitourinary
• Skin
• Brain/Nervous System
• Sarcoma
• Hematological Malignancies
• Lung
• Head and Neck
• Other Cancer Types

Multicancer Screening Market, By Application:

• Clinical
• Research

Multicancer Screening Market, By End User:

• Hospitals
• Diagnostic and Clinical Laboratories
• Academic Research Institutions
• Other End Users

Global Multicancer Screening Market, By Region:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the global multicancer screening market.

Available Customizations:

• With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Multicancer Screening Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value & Volume
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Laboratory Developed Tests (LDTs), In-Vitro Diagnostics (IVDs))
  • 5.2.2. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), and Other Technologies)
  • 5.2.3. By Sample (Tissue, Blood, Saliva and Buccal Swab, and Others)
  • 5.2.4. By Method (DNA, RNA, and Proteins)
  • 5.2.5. By Cancer Type (Breast and Gynecologic, Gastrointestinal, Endocrine, Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological Malignancies, Lung, Head and Neck, and Other Cancer Types)
  • 5.2.6. By Application (Clinical, Research)
  • 5.2.7. By End User (Hospitals, Diagnostic and Clinical Laboratories, Academic Research Institutions, and Other End Users)
  • 5.2.8. By Region
  • 5.2.9. By Company (2022)
• 5.3. Product Market Map

6. North America Multicancer Screening Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value & Volume
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Technology
  • 6.2.3. By Sample
  • 6.2.4. By Method
  • 6.2.5. By Cancer Type
  • 6.2.6. By Application
  • 6.2.7. By End User
  • 6.2.8. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Multicancer Screening Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value & Volume
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Sample
      • 6.3.1.2.4. By Method
      • 6.3.1.2.5. By Cancer Type
      • 6.3.1.2.6. By Application
      • 6.3.1.2.7. By End User
  • 6.3.2. Mexico Multicancer Screening Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value & Volume
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Sample
      • 6.3.2.2.4. By Method
      • 6.3.2.2.5. By Cancer Type
      • 6.3.2.2.6. By Application
      • 6.3.2.2.7. By End User
  • 6.3.3. Canada Multicancer Screening Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value & Volume
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Sample
      • 6.3.3.2.4. By Method
      • 6.3.3.2.5. By Cancer Type
      • 6.3.3.2.6. By Application
      • 6.3.3.2.7. By End User

7. Europe Multicancer Screening Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value & Volume
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Technology
  • 7.2.3. By Sample
  • 7.2.4. By Method
  • 7.2.5. By Cancer Type
  • 7.2.6. By Application
  • 7.2.7. By End User
  • 7.2.8. By Country
• 7.3 Europe: Country Analysis
  • 7.3.1. France Multicancer Screening Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value & Volume
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Sample
      • 7.3.1.2.4. By Method
      • 7.3.1.2.5. By Cancer Type
      • 7.3.1.2.6. By Application
      • 7.3.1.2.7. By End User
  • 7.3.2. Germany Multicancer Screening Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value & Volume
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Sample
      • 7.3.2.2.4. By Method
      • 7.3.2.2.5. By Cancer Type
      • 7.3.2.2.6. By Application
      • 7.3.2.2.7. By End User
  • 7.3.3. United Kingdom Multicancer Screening Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value & Volume
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Sample
      • 7.3.3.2.4. By Method
      • 7.3.3.2.5. By Cancer Type
      • 7.3.3.2.6. By Application
      • 7.3.3.2.7. By End User
  • 7.3.4. Italy Multicancer Screening Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value & Volume
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Sample
      • 7.3.4.2.4. By Method
      • 7.3.4.2.5. By Cancer Type
      • 7.3.4.2.6. By Application
      • 7.3.4.2.7. By End User
  • 7.3.5. Spain Multicancer Screening Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value & Volume
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Sample
      • 7.3.5.2.4. By Method
      • 7.3.5.2.5. By Cancer Type
      • 7.3.5.2.6. By Application
      • 7.3.5.2.7. By End User

8. Asia-Pacific Multicancer Screening Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value & Volume
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Technology
  • 8.2.3. By Sample
  • 8.2.4. By Method
  • 8.2.5. By Cancer Type
  • 8.2.6. By Application
  • 8.2.7. By End User
  • 8.2.8. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Multicancer Screening Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value & Volume
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Sample
      • 8.3.1.2.4. By Method
      • 8.3.1.2.5. By Cancer Type
      • 8.3.1.2.6. By Application
      • 8.3.1.2.7. By End User
  • 8.3.2. India Multicancer Screening Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value & Volume
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Sample
      • 8.3.2.2.4. By Method
      • 8.3.2.2.5. By Cancer Type
      • 8.3.2.2.6. By Application
      • 8.3.2.2.7. By End User
  • 8.3.3. South Korea Multicancer Screening Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value & Volume
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Sample
      • 8.3.3.2.4. By Method
      • 8.3.3.2.5. By Cancer Type
      • 8.3.3.2.6. By Application
      • 8.3.3.2.7. By End User
  • 8.3.4. Japan Multicancer Screening Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value & Volume
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Sample
      • 8.3.4.2.4. By Method
      • 8.3.4.2.5. By Cancer Type
      • 8.3.4.2.6. By Application
      • 8.3.4.2.7. By End User
  • 8.3.5. Australia Multicancer Screening Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value & Volume
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Sample
      • 8.3.5.2.4. By Method
      • 8.3.5.2.5. By Cancer Type
      • 8.3.5.2.6. By Application
      • 8.3.5.2.7. By End User

9. South America Multicancer Screening Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value & Volume
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Technology
  • 9.2.3. By Sample
  • 9.2.4. By Method
  • 9.2.5. By Cancer Type
  • 9.2.6. By Application
  • 9.2.7. By End User
  • 9.2.8. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Multicancer Screening Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value & Volume
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Sample
      • 9.3.1.2.4. By Method
      • 9.3.1.2.5. By Cancer Type
      • 9.3.1.2.6. By Application
      • 9.3.1.2.7. By End User
  • 9.3.2. Argentina Multicancer Screening Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value & Volume
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Sample
      • 9.3.2.2.4. By Method
      • 9.3.2.2.5. By Cancer Type
      • 9.3.2.2.6. By Application
      • 9.3.2.2.7. By End User
  • 9.3.3. Colombia Multicancer Screening Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value & Volume
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Sample
      • 9.3.3.2.4. By Method
      • 9.3.3.2.5. By Cancer Type
      • 9.3.3.2.6. By Application
      • 9.3.3.2.7. By End User

10. Middle East and Africa Multicancer Screening Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value & Volume
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Technology
  • 10.2.3. By Sample
  • 10.2.4. By Method
  • 10.2.5. By Cancer Type
  • 10.2.6. By Application
  • 10.2.7. By End User
  • 10.2.8. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Multicancer Screening Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value & Volume
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Sample
      • 10.3.1.2.4. By Method
      • 10.3.1.2.5. By Cancer Type
      • 10.3.1.2.6. By Application
      • 10.3.1.2.7. By End User
  • 10.3.2. Saudi Arabia Multicancer Screening Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value & Volume
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Sample
      • 10.3.2.2.4. By Method
      • 10.3.2.2.5. By Cancer Type
      • 10.3.2.2.6. By Application
      • 10.3.2.2.7. By End User
  • 10.3.3. UAE Multicancer Screening Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value & Volume
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Sample
      • 10.3.3.2.4. By Method
      • 10.3.3.2.5. By Cancer Type
      • 10.3.3.2.6. By Application
      • 10.3.3.2.7. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Company Snapshot
• 15.3. Products & Services
• 15.4. Financials (In case of listed companies)
• 15.5. Recent Developments
• 15.6. SWOT Analysis
  • 15.6.1. Agilent Technologies, Inc.
  • 15.6.2. Atara Biotherapeutics, Inc.
  • 15.6.3. Burning Rock Biotech Limited
  • 15.6.4. Exact Sciences Corp.
  • 15.6.5. F. Hoffmann-La Roche Ltd.
  • 15.6.6. Fulgent Genetics, Inc.
  • 15.6.7. Genecast Biotechnology Co., Ltd.
  • 15.6.8. Guardant Health, Inc.
  • 15.6.9. Illumina, Inc. (GRAIL, LLC.)
  • 15.6.10. Konica Minolta, Inc. (Ambry Genetics.)

16. Strategic Recommendations

17. About Us & Disclaimer